Astrazeneca Says Saphnelo SC Showed Significant Reduction In Lupus Disease Activity

Jan 6 (Reuters) - AstraZeneca PLC AZN.L:

• SAPHNELO SELF-ADMINISTRATION TULIP-SC TRIAL DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY

• SAPHNELO ENABLED ORAL CORTICOSTEROID REDUCTION WHILE MAINTAINING CLINICAL RESPONSE IN A KEY SECONDARY ENDPOINT

• PATIENTS ACHIEVED REMISSION WITH SAPHNELO AS DEMONSTRATED IN AN EXPLORATORY ENDPOINT